VJOncology is committed to improving our service to you

ELCC 2019 | Molecularly-guided treatment of advanced NSCLC: ALK inhibitor sequencing

VJOncology is committed to improving our service to you

Alice Tsang Shaw

Alice Tsang Shaw, MD, PhD, Massachusetts General Hospital, Boston, MA, discusses the importance of screening for genetic alterations when treating patients with advanced non-small cell lung cancer (NSCLC). She explains how the sequencing of ALK inhibitors could be molecularly guided. This video was recorded at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter